Detalhe da pesquisa
1.
Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.
Cancer Chemother Pharmacol
; 89(4): 515-527, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35298699
2.
A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
Blood Adv
; 4(5): 906-919, 2020 03 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32150609
3.
Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies.
J Med Chem
; 62(3): 1523-1540, 2019 02 14.
Artigo
Inglês
| MEDLINE | ID: mdl-30624936
4.
Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors.
ACS Med Chem Lett
; 7(4): 408-12, 2016 Apr 14.
Artigo
Inglês
| MEDLINE | ID: mdl-27096050
5.
Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
J Med Chem
; 59(13): 6407-30, 2016 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-27285051
6.
Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Cancer Res
; 68(16): 6680-7, 2008 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18701492